Alzheimer’s Therapeutics Market
A recent market study published by Future Market Insights (FMI) on the Alzheimer’s therapeutics market offers a global industry analysis for 2017-2021 and an opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the Alzheimer’s therapeutics market, the growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may make a huge impact on the development of the Alzheimer’s therapeutics market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.
The report provides detailed information about the current and future growth prospects of the Alzheimer’s therapeutics market in the most comprehensive way for a better understanding of readers.
Key Segments of Alzheimer’s Therapeutics Market
Future Market Insight study on the Alzheimer’s therapeutics market offers information divided into four important segments— drug name, drug class, distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug Name
Donepezil
Rivastigmine
Memantine
Galantamine
Manufactured Combination of Memantine and Donepezil
Drug Class
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Manufactured Combination
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)
Chapter 1 – Executive Summary
The report commences with the executive summary of the Alzheimer’s therapeutics market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the Alzheimer’s therapeutics market as well as the key trends impacting the market.
Chapter 2 – Market Overview
Readers can find detailed taxonomy and definition/scope/limitations and inclusions and exclusions of the Alzheimer’s therapeutics market in this chapter, which helps readers understand basic information about the Alzheimer’s therapeutics market.
Chapter 3 – Key Market Trends
This section highlights the key trends impacting the Alzheimer’s therapeutics market, which will help readers in understanding the current trends and their impact on market growth.
Chapter 4 – Key Success Factors
This chapter explains the key success factors which include the treatment regime, disease epidemiology of Alzheimer’s disease, product adoption/ usage analysis by region, recent product approval, key promotional strategies by market players, regulatory scenario, pipeline assessment, Porter’s Analysis, PESTLE analysis, supply chain analysis, dosage patterns, and impact of Aduhelm Drug that are expected to augment the growth of the Alzheimer’s therapeutics market during the forecast period.
Chapter 5 – Global Alzheimer’s Therapeutics Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
This section explains the global market value or size analysis and forecast for the Alzheimer’s therapeutics market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2022), and an incremental $ opportunity for the forecast period (2022–2032).
Chapter 6 – Market Background
This chapter explains the key macroeconomic factors that are expected to influence the growth of the Alzheimer’s therapeutics market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the Alzheimer’s therapeutics market, which include the drivers, restraints, and opportunity analysis. This section also provides the current and expected impact of COVID-19 on the Alzheimer’s therapeutics market
Chapter 7– Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, by Drug Name
Based on drug name, the Alzheimer’s therapeutics market is segmented into drug names (donepezil, rivastigmine, memantine, galantamine and manufactured combination of memantine and donepezil). In this chapter, readers can find information about a detailed analysis of the market by different drugs available in the Alzheimer’s therapeutics market and their growth over the forecast period.
Chapter 8 – Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Based on drug class, the Alzheimer’s therapeutics market is segmented into drug classes (cholinesterase Inhibitors, NMDA Receptor antagonists and manufactured combinations). In this chapter, readers can find information about a detailed analysis of the market by drug class available in the Alzheimer’s therapeutics market and their growth over the forecast period.
Chapter 9 – Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channel
Based on distribution channels, the Alzheimer’s therapeutics market is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies. In this chapter, readers can find information about a detailed analysis of the market by different distribution channel available in the Alzheimer’s therapeutics market and their growth over the forecast period.
Chapter 10 – Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, by Region
This chapter explains how the Alzheimer’s therapeutics market will grow across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania and the Middle East and Africa (MEA).
Chapter 11 – North America Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of the North America Alzheimer’s therapeutics market along with a country-wise assessment including the U.S. and Canada. Readers can also find key takeaways from this region, and market growth based on drug name, drug class, distribution channel and country of the Alzheimer’s therapeutics market in the North American region.
Chapter 12 – Latin America Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes the growth prospects of the Alzheimer’s therapeutics market in leading countries such as Brazil, Mexico, Argentina and the rest of Latin America. Readers can find thorough information about the growth parameters based on drug name, drug class, distribution channel and country in the Latin America Alzheimer’s therapeutics market during 2022-2032.
Chapter 13 – Europe Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes the growth prospects of the Alzheimer’s therapeutics market based on the development of new product development, regulatory approvals, and country in several European countries such as the U.K., Germany, France, Italy, Spain, Russia, and the Rest of Europe are included in this chapter.
Chapter 14 – East Asia Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032
China, Japan, and South Korea are the prime subjects of assessment to obtain the growth prospects of the East Asia Alzheimer’s therapeutics market. Also, in this chapter, readers can find thorough information about the growth parameters of the East Asia Alzheimer’s therapeutics market through 2032.
Chapter 15 – South Asia Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032
India, Thailand, Indonesia, Malaysia, and the rest of South Asia are the prime subjects of assessment to obtain the growth prospects of the Alzheimer’s therapeutics market. Also, in this chapter, readers can find thorough information about the growth parameters of the South Asia Alzheimer’s therapeutics market growth over the forecast period.
Chapter 16 – Oceania Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032
This chapter consists of important parameters that have a huge impact on the growth of the Alzheimer’s therapeutics market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania Alzheimer’s therapeutics market.
Chapter 17 – Middle East and Africa Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032
This chapter provides information on how the Alzheimer’s therapeutics market will grow in the major countries in the MEA region, such as GCC Countries, Turkey and the rest of MEA during 2022-2032.
Chapter 18 – Market Structure Analysis
This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key players operating in the Alzheimer’s therapeutics market.
Chapter 19 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the Alzheimer’s therapeutics market including company overview, revenue shares, strategic overview, and recent company developments. Some of the major market players featured in the report are Biogen Inc, AbbVie, Inc, Teva Pharmaceuticals Ltd, Eisai Co., Ltd., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc, Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd., Cipla Ltd., Torrent pharmaceuticals ltd., Unichem laboratories ltd, and Lannett Inc.
Chapter 20 – Assumptions and Acronyms Used
This chapter includes a list of acronyms and assumptions that provide a base for the information and statistics included in the report.
Chapter 21 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about Alzheimer’s therapeutics market.
Sources and Primary Research Splits (%)
Industry Interactions
Key Designations
C - Level Executives
Marketing Directors
Product Managers
Business Development Officers
Production Managers
Procurement Heads
Sales Executives
Stakeholder Category
Distributors
Traders
Raw Material Suppliers
Industry Experts
References Catalogue
Industry Publications
World Health Organizations (WHO)
National Institute of Health (NIH)
Factiva
Company Press Releases
Annual Reports and Investor Presentations
Research Papers
Government Websites and Publications
Company Websites,
Morningstar
World bank Data
LinkedIn
Zoom info
Salesforce
- 1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply-Side Trends
- 1.4. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusions and Exclusions
- 3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Innovation / Development Trends
- 4. Key Success Factors
- 4.1. Treatment Regime
- 4.2. Disease epidemiology of Alzheimer’s disease
- 4.3. Product Adoption/ Usage Analysis, by region
- 4.4. Recent Product Approval
- 4.5. Key Promotional Strategies by Market Players
- 4.6. Regulatory Scenario
- 4.7. Pipeline Assessment
- 4.8. Porter’s Analysis
- 4.9. PESTLE Analysis
- 4.10. Supply Chain Analysis
- 4.11. Dosage Patterns
- 4.12. Impact of Aduhelm Drug
- 5. Global Alzheimer’s Therapeutics Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
- 5.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
- 5.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
- 5.2.1. Y-o-Y Growth Trend Analysis
- 5.2.2. Absolute $ Opportunity Analysis
- 6. Market Background
- 6.1. Macro-Economic Factors
- 6.1.1. Global Healthcare Spending Overview
- 6.1.2. Global Pharmaceutical Market Outlook
- 6.1.3. Global Prevalence of Dementia
- 6.2. Forecast Factors - Relevance & Impact
- 6.2.1. Rising ageing population
- 6.2.2. Growing investment in healthcare expenditure
- 6.2.3. Growing advancements in diagnostic technologies
- 6.2.4. Rising prevalence of neurodegenerative disease
- 6.2.5. Adverse effects may impact the market growth
- 6.2.6. Key Strategic Developments
- 6.2.7. Product Adoption Rate and Demand
- 6.2.8. New Product Launches
- 6.3. COVID-19 Crisis – Impact Assessment
- 6.3.1. COVID-19 Crisis Analysis
- 6.3.2. Current GDP Projection and Probable Impact
- 6.3.3. Short-Mid-Long Term Outlook
- 6.3.4. Impact of COVID-19 on caregivers of Alzheimer’s disease
- 6.3.5. Impact of COVID-19 on Alzheimer’s disease diagnosis
- 6.4. Market Dynamics
- 6.4.1. Drivers
- 6.4.2. Restraints
- 6.4.3. Opportunity Analysis
- 6.5. Global Supply Demand Analysis
- 7. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
- 7.1. Introduction / Key Findings
- 7.2. Historical Market Size (US$ Mn) Analysis, By Drug Name, 2017–2021
- 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Name, 2022–2032
- 7.3.1. Donepezil
- 7.3.2. Rivastigmine
- 7.3.3. Memantine
- 7.3.4. Galantamine
- 7.3.5. Manufactured Combination of memantine and donepezil
- 7.4. Market Attractiveness Analysis, By Drug Name
- 8. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2017–2021
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2022–2032
- 8.3.1. Cholinesterase Inhibitors
- 8.3.2. NMDA Receptor Antagonists
- 8.3.3. Manufactured Combination
- 8.4. Market Attractiveness Analysis, By Drug Class
- 9. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2017–2021
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2022–2032
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Drug Stores
- 9.3.4. Online Pharmacies
- 9.4. Market Attractiveness Analysis, By Distribution Channel
- 10. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, by Region
- 10.1. Introduction
- 10.2. Historical Market Size (US$ Mn) Analysis, By Region, 2017–2021
- 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2022–2032
- 10.3.1. North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. East Asia
- 10.3.5. South Asia
- 10.3.6. Oceania
- 10.3.7. Middle East and Africa (MEA)
- 10.4. Market Attractiveness Analysis, By Region
- 11. North America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
- 11.1. Introduction
- 11.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
- 11.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
- 11.3.1. By Country
- 11.3.1.1. U.S.
- 11.3.1.2. Canada
- 11.3.2. By Drug Name
- 11.3.3. By Drug Class
- 11.3.4. By Distribution Channel
- 11.4. Market Attractiveness Analysis
- 11.4.1. By Country
- 11.4.2. By Drug Name
- 11.4.3. By Drug Class
- 11.4.4. By Distribution Channel
- 11.5. Key Market Participants - Intensity Mapping
- 11.6. Drivers and Restraints - Impact Analysis
- 11.7. Country Level Analysis & Forecast
- 11.7.1. U.S. Alzheimer’s Therapeutics Market Analysis
- 11.7.1.1. Introduction
- 11.7.1.2. Market Analysis and Forecast, By Market Taxonomy
- 11.7.1.2.1. By Drug Name
- 11.7.1.2.2. By Drug Class
- 11.7.1.2.3. By Distribution Channel
- 11.7.2. Canada Alzheimer’s Therapeutics Market Analysis
- 11.7.2.1. Introduction
- 11.7.2.2. Market Analysis and Forecast, By Market Taxonomy
- 11.7.2.2.1. By Drug Name
- 11.7.2.2.2. By Drug Class
- 11.7.2.2.3. By Distribution Channel
- 12. Latin America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
- 12.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
- 12.3.1. By Country
- 12.3.1.1. Mexico
- 12.3.1.2. Brazil
- 12.3.1.3. Argentina
- 12.3.1.4. Rest of Latin America
- 12.3.2. By Drug Name
- 12.3.3. By Drug Class
- 12.3.4. By Distribution Channel
- 12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Drug Name
- 12.4.3. By Drug Class
- 12.4.4. By Distribution Channel
- 12.5. Key Market Participants - Intensity Mapping
- 12.6. Drivers and Restraints - Impact Analysis
- 12.7. Country Level Analysis & Forecast
- 12.7.1. Mexico Alzheimer’s Therapeutics Market Analysis
- 12.7.1.1. Introduction
- 12.7.1.2. Market Analysis and Forecast, By Market Taxonomy
- 12.7.1.2.1. By Drug Name
- 12.7.1.2.2. By Drug Class
- 12.7.1.2.3. By Distribution Channel
- 12.7.2. Brazil Alzheimer’s Therapeutics Market Analysis
- 12.7.2.1. Introduction
- 12.7.2.2. Market Analysis and Forecast, By Market Taxonomy
- 12.7.2.2.1. By Drug Name
- 12.7.2.2.2. By Drug Class
- 12.7.2.2.3. By Distribution Channel
- 12.7.3. Argentina Alzheimer’s Therapeutics Market Analysis
- 12.7.3.1. Introduction
- 12.7.3.2. Market Analysis and Forecast, By Market Taxonomy
- 12.7.3.2.1. By Drug Name
- 12.7.3.2.2. By Drug Class
- 12.7.3.2.3. By Distribution Channel
- 13. Europe Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
- 13.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
- 13.3.1. By Country
- 13.3.1.1. Germany
- 13.3.1.2. Italy
- 13.3.1.3. France
- 13.3.1.4. U.K.
- 13.3.1.5. Spain
- 13.3.1.6. BENELUX
- 13.3.1.7. Nordic Countries
- 13.3.1.8. Russia
- 13.3.1.9. Rest of Europe
- 13.3.2. By Country
- 13.3.3. By Drug Name
- 13.3.4. By Drug Class
- 13.3.5. By Distribution Channel
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug Name
- 13.4.3. By Drug Class
- 13.4.4. By Distribution Channel
- 13.5. Key Market Participants - Intensity Mapping
- 13.6. Drivers and Restraints - Impact Analysis
- 13.7. Country Level Analysis & Forecast
- 13.7.1. Germany Alzheimer’s Therapeutics Market Analysis
- 13.7.1.1. Introduction
- 13.7.1.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.1.2.1. By Drug Name
- 13.7.1.2.2. By Drug Class
- 13.7.1.2.3. By Distribution Channel
- 13.7.2. Italy Alzheimer’s Therapeutics Market Analysis
- 13.7.2.1. Introduction
- 13.7.2.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.2.2.1. By Drug Name
- 13.7.2.2.2. By Drug Class
- 13.7.2.2.3. By Distribution Channel
- 13.7.3. France Alzheimer’s Therapeutics Market Analysis
- 13.7.3.1. Introduction
- 13.7.3.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.3.2.1. By Drug Name
- 13.7.3.2.2. By Drug Class
- 13.7.3.2.3. By Distribution Channel
- 13.7.4. U.K. Alzheimer’s Therapeutics Market Analysis
- 13.7.4.1. Introduction
- 13.7.4.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.4.2.1. By Drug Name
- 13.7.4.2.2. By Drug Class
- 13.7.4.2.3. By Distribution Channel
- 13.7.5. Spain Alzheimer’s Therapeutics Market Analysis
- 13.7.5.1. Introduction
- 13.7.5.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.5.2.1. By Drug Name
- 13.7.5.2.2. By Drug Class
- 13.7.5.2.3. By Distribution Channel
- 13.7.6. BENELUX Alzheimer’s Therapeutics Market Analysis
- 13.7.6.1. Introduction
- 13.7.6.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.6.2.1. By Drug Name
- 13.7.6.2.2. By Drug Class
- 13.7.6.2.3. By Distribution Channel
- 13.7.7. Nordic Countries Alzheimer’s Therapeutics Market Analysis
- 13.7.7.1. Introduction
- 13.7.7.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.7.2.1. By Drug Name
- 13.7.7.2.2. By Drug Class
- 13.7.7.2.3. By Distribution Channel
- 13.7.8. Russia Alzheimer’s Therapeutics Market Analysis
- 13.7.8.1. Introduction
- 13.7.8.2. Market Analysis and Forecast, By Market Taxonomy
- 13.7.8.2.1. By Drug Name
- 13.7.8.2.2. By Drug Class
- 13.7.8.2.3. By Distribution Channel
- 14. East Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
- 14.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
- 14.3.1. By Country
- 14.3.1.1. China
- 14.3.1.2. Japan
- 14.3.1.3. South Korea
- 14.3.2. By Country
- 14.3.3. By Drug Name
- 14.3.4. By Drug Class
- 14.3.5. By Distribution Channel
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug Name
- 14.4.3. By Drug Class
- 14.4.4. By Distribution Channel
- 14.5. Key Market Participants - Intensity Mapping
- 14.6. Drivers and Restraints - Impact Analysis
- 14.7. Country Level Analysis & Forecast
- 14.7.1. China Alzheimer’s Therapeutics Market Analysis
- 14.7.1.1. Introduction
- 14.7.1.2. Market Analysis and Forecast, By Market Taxonomy
- 14.7.1.2.1. By Drug Name
- 14.7.1.2.2. By Drug Class
- 14.7.1.2.3. By Distribution Channel
- 14.7.2. Japan Alzheimer’s Therapeutics Market Analysis
- 14.7.2.1. Introduction
- 14.7.2.2. Market Analysis and Forecast, By Market Taxonomy
- 14.7.2.2.1. By Drug Name
- 14.7.2.2.2. By Drug Class
- 14.7.2.2.3. By Distribution Channel
- 14.7.3. South Korea Alzheimer’s Therapeutics Market Analysis
- 14.7.3.1. Introduction
- 14.7.3.2. Market Analysis and Forecast, By Market Taxonomy
- 14.7.3.2.1. By Drug Name
- 14.7.3.2.2. By Drug Class
- 14.7.3.2.3. By Distribution Channel
- 15. South Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
- 15.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
- 15.3.1. By Country
- 15.3.1.1. India
- 15.3.1.2. Thailand
- 15.3.1.3. Malaysia
- 15.3.1.4. Philippines
- 15.3.1.5. Indonesia
- 15.3.1.6. Vietnam
- 15.3.1.7. Rest of South Asia
- 15.3.2. By Drug Name
- 15.3.3. By Drug Class
- 15.3.4. By Distribution Channel
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug Name
- 15.4.3. By Drug Class
- 15.4.4. By Distribution Channel
- 15.5. Key Market Participants - Intensity Mapping
- 15.6. Drivers and Restraints - Impact Analysis
- 15.7. Country Level Analysis & Forecast
- 15.7.1. India Alzheimer’s Therapeutics Market Analysis
- 15.7.1.1. Introduction
- 15.7.1.2. Market Analysis and Forecast, By Market Taxonomy
- 15.7.1.2.1. By Drug Name
- 15.7.1.2.2. By Drug Class
- 15.7.1.2.3. By Distribution Channel
- 15.7.2. Thailand Alzheimer’s Therapeutics Market Analysis
- 15.7.2.1. Introduction
- 15.7.2.2. Market Analysis and Forecast, By Market Taxonomy
- 15.7.2.2.1. By Drug Name
- 15.7.2.2.2. By Drug Class
- 15.7.2.2.3. By Distribution Channel
- 15.7.3. Malaysia Alzheimer’s Therapeutics Market Analysis
- 15.7.3.1. Introduction
- 15.7.3.2. Market Analysis and Forecast, By Market Taxonomy
- 15.7.3.2.1. By Drug Name
- 15.7.3.2.2. By Drug Class
- 15.7.3.2.3. By Distribution Channel
- 15.7.4. Philippines Alzheimer’s Therapeutics Market Analysis
- 15.7.4.1. Introduction
- 15.7.4.2. Market Analysis and Forecast, By Market Taxonomy
- 15.7.4.2.1. By Drug Name
- 15.7.4.2.2. By Drug Class
- 15.7.4.2.3. By Distribution Channel
- 15.7.5. Indonesia Alzheimer’s Therapeutics Market Analysis
- 15.7.5.1. Introduction
- 15.7.5.2. Market Analysis and Forecast, By Market Taxonomy
- 15.7.5.2.1. By Drug Name
- 15.7.5.2.2. By Drug Class
- 15.7.5.2.3. By Distribution Channel
- 15.7.6. Vietnam Alzheimer’s Therapeutics Market Analysis
- 15.7.6.1. Introduction
- 15.7.6.2. Market Analysis and Forecast, By Market Taxonomy
- 15.7.6.2.1. By Drug Name
- 15.7.6.2.2. By Drug Class
- 15.7.6.2.3. By Distribution Channel
- 15.7.7. Rest of South Asia Alzheimer’s Therapeutics Market Analysis
- 15.7.7.1. Introduction
- 15.7.7.2. Market Analysis and Forecast, By Market Taxonomy
- 15.7.7.2.1. By Drug Name
- 15.7.7.2.2. By Drug Class
- 15.7.7.2.3. By Distribution Channel
- 16. Oceania Alzheimer’s Therapeutics Market 2017-2021 and Forecast 2022-2032
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
- 16.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
- 16.3.1. By Country
- 16.3.2. Australia
- 16.3.3. New Zealand
- 16.3.4. By Drug Name
- 16.3.5. By Drug Class
- 16.3.6. By Distribution Channel
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug Name
- 16.4.3. By Drug Class
- 16.4.4. By Distribution Channel
- 16.5. Key Market Participants - Intensity Mapping
- 16.6. Drivers and Restraints - Impact Analysis
- 16.7. Country Level Analysis & Forecast
- 16.7.1. Australia Alzheimer’s Therapeutics Market Analysis
- 16.7.2.Introduction
- 16.7.3. Market Analysis and Forecast, By Market Taxonomy
- 16.7.3.1. By Drug Name
- 16.7.3.2.By Drug Class
- 16.7.3.3. By Distribution Channel
- 16.7.2. New Zealand Alzheimer’s Therapeutics Market Analysis
- 16.7.2.1. Introduction
- 16.7.2.2. Market Analysis and Forecast, By Market Taxonomy
- 16.7.2.2.1. By Drug Name
- 16.7.2.2.2. By Drug Class
- 16.7.2.2.3. By Distribution Channel
- 17. Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
- 17.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
- 17.3.1. By Country
- 17.3.1.1. GCC Countries
- 17.3.1.2. Israel
- 17.3.1.3. Turkey
- 17.3.1.4. South Africa
- 17.3.1.5. North Africa
- 17.3.1.6. Rest of Middle East and Africa
- 17.3.2. By Drug Name
- 17.3.3. By Drug Class
- 17.3.4. By Distribution Channel
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug Name
- 17.4.3. By Drug Class
- 17.4.4. By Distribution Channel
- 17.5. Key Market Participants - Intensity Mapping
- 17.6. Drivers and Restraints - Impact Analysis
- 17.7. Country Level Analysis & Forecast
- 17.7.1. GCC Countries Alzheimer’s Therapeutics Market Analysis
- 17.7.1.1. Introduction
- 17.7.1.2. Market Analysis and Forecast, By Market Taxonomy
- 17.7.1.2.1. By Drug Name
- 17.7.1.2.2. By Drug Class
- 17.7.1.2.3. By Distribution Channel
- 17.7.2. Israel Alzheimer’s Therapeutics Market Analysis
- 17.7.2.1. Introduction
- 17.7.2.2. Market Analysis and Forecast, By Market Taxonomy
- 17.7.2.2.1. By Drug Name
- 17.7.2.2.2. By Drug Class
- 17.7.2.2.3. By Distribution Channel
- 17.7.3. Turkey Alzheimer’s Therapeutics Market Analysis
- 17.7.3.1. Introduction
- 17.7.3.2. Market Analysis and Forecast, By Market Taxonomy
- 17.7.3.2.1. By Drug Name
- 17.7.3.2.2. By Drug Class
- 17.7.3.2.3. By Distribution Channel
- 17.7.4. South Africa Alzheimer’s Therapeutics Market Analysis
- 17.7.4.1. Introduction
- 17.7.4.2. Market Analysis and Forecast, By Market Taxonomy
- 17.7.4.2.1. By Drug Name
- 17.7.4.2.2. By Drug Class
- 17.7.4.2.3. By Distribution Channel
- 17.7.5. North Africa Alzheimer’s Therapeutics Market Analysis
- 17.7.5.1. Introduction
- 17.7.5.2. Market Analysis and Forecast, By Market Taxonomy
- 17.7.5.2.1. By Drug Name
- 17.7.5.2.2. By Drug Class
- 17.7.5.2.3. By Distribution Channel
- 17.7.6. Rest of MEA Alzheimer’s Therapeutics Market Analysis
- 17.7.6.1. Introduction
- 17.7.6.2. Market Analysis and Forecast, By Market Taxonomy
- 17.7.6.2.1. By Drug Name
- 17.7.6.2.2. By Drug Class
- 17.7.6.2.3. By Distribution Channel
- 18. Market Structure Analysis
- 18.1. Market Analysis, By Tier of Companies
- 18.2. Market Share Analysis of Top Players
- 18.3. Market Presence Analysis
- 19. Competition Analysis
- 19.1. Competition Dashboard
- 19.2. Key Development Analysis
- 19.3. Competition Benchmarking
- 19.4. Competition Deep Dive
- 19.4.1. Biogen Inc.
- 19.4.1.1. Overview
- 19.4.1.2. Product Portfolio
- 19.4.1.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.1.4. Sales Footprint
- 19.4.1.5. Strategy Overview
- 19.4.2. AbbVie, Inc.
- 19.4.2.1. Overview
- 19.4.2.2. Product Portfolio
- 19.4.2.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.2.4. Sales Footprint
- 19.4.2.5. Strategy Overview
- 19.4.3. Teva Pharmaceuticals Ltd.
- 19.4.3.1. Overview
- 19.4.3.2. Product Portfolio
- 19.4.3.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.3.4. Sales Footprint
- 19.4.3.5. Strategy Overview
- 19.4.4. Eisai Co., Ltd.
- 19.4.4.1. Overview
- 19.4.4.2. Product Portfolio
- 19.4.4.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.4.4. Sales Footprint
- 19.4.4.5. Strategy Overview
- 19.4.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- 19.4.5.1. Overview
- 19.4.5.2. Product Portfolio
- 19.4.5.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.5.4. Sales Footprint
- 19.4.5.5. Strategy Overview
- 19.4.6. Novartis AG
- 19.4.6.1. Overview
- 19.4.6.2. Product Portfolio
- 19.4.6.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.6.4. Sales Footprint
- 19.4.6.5. Strategy Overview
- 19.4.7. Zydus Lifesciences Ltd (CADILA)
- 19.4.7.1. Overview
- 19.4.7.2. Product Portfolio
- 19.4.7.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.7.4. Sales Footprint
- 19.4.7.5. Strategy Overview
- 19.4.8. Sun Pharmaceutical Industries Ltd.
- 19.4.8.1. Overview
- 19.4.8.2. Product Portfolio
- 19.4.8.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.8.4. Sales Footprint
- 19.4.8.5. Strategy Overview
- 19.4.9. Dr. Reddy's Laboratories Ltd
- 19.4.9.1. Overview
- 19.4.9.2. Product Portfolio
- 19.4.9.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.9.4. Sales Footprint
- 19.4.9.5. Strategy Overview
- 19.4.10. Aurobindo Pharma Ltd
- 19.4.10.1. Overview
- 19.4.10.2. Product Portfolio
- 19.4.10.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.10.4. Sales Footprint
- 19.4.10.5. Strategy Overview
- 19.4.11. Amneal Pharmaceuticals Inc.
- 19.4.11.1. Overview
- 19.4.11.2. Product Portfolio
- 19.4.11.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.11.4. Sales Footprint
- 19.4.11.5. Strategy Overview
- 19.4.12. Macleods Pharmaceuticals Ltd.
- 19.4.12.1. Overview
- 19.4.12.2. Product Portfolio
- 19.4.12.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.12.4. Sales Footprint
- 19.4.12.5. Strategy Overview
- 19.4.13. Viatris Inc.
- 19.4.13.1. Overview
- 19.4.13.2. Product Portfolio
- 19.4.13.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.13.4. Sales Footprint
- 19.4.13.5. Strategy Overview
- 19.4.14. Lupin Ltd
- 19.4.14.1. Overview
- 19.4.14.2. Product Portfolio
- 19.4.14.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.14.4. Sales Footprint
- 19.4.14.5. Strategy Overview
- 19.4.15. Cipla Ltd.
- 19.4.15.1. Overview
- 19.4.15.2. Product Portfolio
- 19.4.15.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.15.4. Sales Footprint
- 19.4.15.5. Strategy Overview
- 19.4.16. Torrent pharmaceuticals ltd.
- 19.4.16.1. Overview
- 19.4.16.2. Product Portfolio
- 19.4.16.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.16.4. Sales Footprint
- 19.4.16.5. Strategy Overview
- 19.4.17. Unichem laboratories ltd
- 19.4.17.1. Overview
- 19.4.17.2. Product Portfolio
- 19.4.17.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.17.4. Sales Footprint
- 19.4.17.5. Strategy Overview
- 19.4.18. Lannett Inc.
- 19.4.18.1. Overview
- 19.4.18.2. Product Portfolio
- 19.4.18.3. Profitability by Market Segments (Product/Channel/Region)
- 19.4.18.4. Sales Footprint
- 19.4.18.5. Strategy Overview
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook